|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol, or diabetes.
Hypersensitivity to sympathomimetic amines; advanced arteriosclerosis; symptomatic CV disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse; during or within 14 days following the administration of an MAOI.
Cardiovascular Regurgitant cardiac valvular disease; palpitation; tachycardia; hypertension. CNS Overstimulation; restlessness; dizziness; insomnia; euphoria; dysphoria; tremor; headache; psychotic episodes. Dermatologic Allergic urticaria. GI Dry mouth; unpleasant taste; diarrhea; constipation. Genitourinary Impotence; changes in libido. Respiratory Primary pulmonary hypertension.
Guanethidine May decrease hypotensive effect of guanethidine. MAOIs (eg, phenelzine); furazolidone May cause hypertensive crisis and intracranial hemorrhage. Selective serotonin reuptake inhibitors (eg, fluoxetine) Sympathomimetic effects of phentermine and risk of “serotonin syndrome” may be increased.
Pregnancy Category C . Lactation Undetermined. Children 8?mg dose Safety and efficacy not established in children younger than 12 yr of age. 16 mg dose Safety and efficacy not established in children 16 yr of age or younger. Special Risk Patients Use with caution in patients with glaucoma, hypertension, and diabetes mellitus. Drug dependence Psychological and physical dependence may occur with continued use; this class of drugs has been extensively abused. Tolerance Tolerance to the anorectic effect usually develops within a few weeks. Primary pulmonary hypertension Has been reported with concurrent use of phentermine and fenfluramine or dexfenfluramine. Valvular heart disease Serious regurgitant cardiac valvular disease has been reported with concurrent use of phentermine and fenfluramine or dexfenfluramine.
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Samir Moussa M.D.
Dr. Samer Al-Jneidy
Yaser Habrawi , F.R.C.S.Ed
Dr. Faisal Dibsi
Dr. Tahsin Martini
Dr. Talal Sabouni
Dr. Hani Najjar
Dr . Dirar Abboud